Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Christopher J. Forlenza; Jaclyn Rosenzweig; Audrey Mauguen; Ilia Buhtoiarov; Branko Cuglievan; Hema Dave; Rebecca J. Deyell; Jamie E. Flerlage; Anna Rachel Franklin; Jennifer Krajewski; Kasey J. Leger; Lianna J. Marks; Robin E. Norris; Martha Pacheco; Faye Willen; Adam Paul Yan; Paul D. Harker-Murray; Lisa Giulino-Roth

doi:10.1182/bloodadvances.2022009323

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J. Deyell, Jamie E. Flerlage, Anna Rachel Franklin, Jennifer Krajewski, Kasey J. Leger, Lianna J. Marks, Robin E. Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul D. Harker-Murray, Lisa Giulino-Roth

Pediatrics

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ~50% of patients experiencing a subsequent relapse. The anti-CD30 antibody–drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/ refractory HL.

Original language	English (US)
Pages (from-to)	3225-3231
Number of pages	7
Journal	Blood Advances
Volume	7
Issue number	13
DOIs	https://doi.org/10.1182/bloodadvances.2022009323
State	Published - Jul 11 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2022009323

Cite this

Forlenza, C. J., Rosenzweig, J., Mauguen, A., Buhtoiarov, I., Cuglievan, B., Dave, H., Deyell, R. J., Flerlage, J. E., Franklin, A. R., Krajewski, J., Leger, K. J., Marks, L. J., Norris, R. E., Pacheco, M., Willen, F., Yan, A. P., Harker-Murray, P. D., & Giulino-Roth, L. (2023). Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Advances, 7(13), 3225-3231. https://doi.org/10.1182/bloodadvances.2022009323

Forlenza, CJ, Rosenzweig, J, Mauguen, A, Buhtoiarov, I, Cuglievan, B, Dave, H, Deyell, RJ, Flerlage, JE, Franklin, AR, Krajewski, J, Leger, KJ, Marks, LJ, Norris, RE, Pacheco, M, Willen, F, Yan, AP, Harker-Murray, PD & Giulino-Roth, L 2023, 'Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma', Blood Advances, vol. 7, no. 13, pp. 3225-3231. https://doi.org/10.1182/bloodadvances.2022009323

@article{a72867046d8d4648b9bd6f1602b500c1,

title = "Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma",

abstract = "Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ~50% of patients experiencing a subsequent relapse. The anti-CD30 antibody–drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/ refractory HL.",

author = "Forlenza, {Christopher J.} and Jaclyn Rosenzweig and Audrey Mauguen and Ilia Buhtoiarov and Branko Cuglievan and Hema Dave and Deyell, {Rebecca J.} and Flerlage, {Jamie E.} and Franklin, {Anna Rachel} and Jennifer Krajewski and Leger, {Kasey J.} and Marks, {Lianna J.} and Norris, {Robin E.} and Martha Pacheco and Faye Willen and Yan, {Adam Paul} and Harker-Murray, {Paul D.} and Lisa Giulino-Roth",

note = "Publisher Copyright: {\textcopyright} 2023 by The American Society of Hematology.",

year = "2023",

month = jul,

day = "11",

doi = "10.1182/bloodadvances.2022009323",

language = "English (US)",

volume = "7",

pages = "3225--3231",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "13",

}

TY - JOUR

T1 - Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

AU - Forlenza, Christopher J.

AU - Rosenzweig, Jaclyn

AU - Mauguen, Audrey

AU - Buhtoiarov, Ilia

AU - Cuglievan, Branko

AU - Dave, Hema

AU - Deyell, Rebecca J.

AU - Flerlage, Jamie E.

AU - Franklin, Anna Rachel

AU - Krajewski, Jennifer

AU - Leger, Kasey J.

AU - Marks, Lianna J.

AU - Norris, Robin E.

AU - Pacheco, Martha

AU - Willen, Faye

AU - Yan, Adam Paul

AU - Harker-Murray, Paul D.

AU - Giulino-Roth, Lisa

PY - 2023/7/11

Y1 - 2023/7/11

N2 - Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ~50% of patients experiencing a subsequent relapse. The anti-CD30 antibody–drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/ refractory HL.

AB - Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ~50% of patients experiencing a subsequent relapse. The anti-CD30 antibody–drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/ refractory HL.

UR - http://www.scopus.com/inward/record.url?scp=85166675968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85166675968&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2022009323

DO - 10.1182/bloodadvances.2022009323

M3 - Article

C2 - 36897253

AN - SCOPUS:85166675968

SN - 2473-9529

VL - 7

SP - 3225

EP - 3231

JO - Blood Advances

JF - Blood Advances

IS - 13

ER -

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this